Conatumumab
Based on 1 Customer Validation
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
For research use only. We do not sell to patients.
- Purity : 98.90%
- CAS No.: 896731-82-1
- Molecular Weight:145.44 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF10B/TRAILR2/CD262
In Vitro
Conatumumab (0-10 μg/mL, 4 h) activates caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells[2].
Conatumumab (0-10 μg/mL, 24 h) reduces cell viability in sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Colo205, H-2122, and MiaPaCa2 cells
-
Concentration:0-10 μg/mL
-
Incubation Time:24 h
-
Result:Dose-dependently inhibited cell viability.
In Vivo
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2]
-
Dosage:0, 0.1, 0.3, 1, 3, 10, 30, 100 μg
-
Administration:Intraperitoneal injection (i.p.), twice weekly.
-
Result:Dose-dependently inhibited tumor growth.
Induced caspase-3 activation in tumors (determined by IHC).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5X106 HEPG2 cells with Conatumumab (HY-P99260, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control. -
Immobilized HY-P7307 TRAIL R2/TNFRSF10B Protein, Human (HEK293) can bind Conatumumab. The EC50 for this effect is 2.37 ng/mL.
Chemical Information
-
CAS No. 896731-82-1
-
Appearance Liquid
-
Molecular Weight 145.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Conatumumab]
-
Synonyms
AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. [Content Brief]
[2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)